BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16969334)

  • 21. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of thyroid malignancy in a hot nodule by fluorine-18-fluorodeoxyglucose positron emission tomography.
    Low SC; Sinha AK; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):304-7. PubMed ID: 15902360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD; Vogel WV; Corstens FH; Oyen WJ
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
    Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?
    Slavikova K; Montravers F; Treglia G; Kunikowska J; Kaliska L; Vereb M; Talbot JN; Balogova S
    Curr Radiopharm; 2013 Jun; 6(2):96-105. PubMed ID: 23745775
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ruhlmann M; Ruhlmann J; Görges R; Herrmann K; Antoch G; Keller HW; Ruhlmann V
    Thyroid; 2017 Oct; 27(10):1300-1306. PubMed ID: 28793848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules.
    Sebastianes FM; Cerci JJ; Zanoni PH; Soares J; Chibana LK; Tomimori EK; de Camargo RY; Izaki M; Giorgi MC; Eluf-Neto J; Meneghetti JC; Pereira MA
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4485-8. PubMed ID: 17684046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
    Khan N; Oriuchi N; Higuchi T; Endo K
    Cancer Control; 2005 Oct; 12(4):254-60. PubMed ID: 16258498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid.
    Smith RB; Robinson RA; Hoffman HT; Graham MM
    Otolaryngol Head Neck Surg; 2008 Jan; 138(1):101-6. PubMed ID: 18165002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of F-18FDG PET in thyroid cancer.
    Lind P; Kumnig G; Matschnig S; Heinisch M; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Unterweger O
    Acta Med Austriaca; 2000; 27(2):38-41. PubMed ID: 10812462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
    Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.
    Basu S; Parghane RV
    PET Clin; 2017 Jan; 12(1):27-37. PubMed ID: 27863564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.
    Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F
    Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.